MKGAF.PK: Merck Kgaa Dm 5 Twitter

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, December 19, 2012, 8:39 AM Stimuvax, a lung cancer vaccine that Germany's Merck (MKGAF.PK) has licensed from Oncothyreon (ONTY), failed to improve overall survival in a Phase III study. However, "notable treatment effects were observed in certain subgroups of patients." That's not enough to convince analysts: "Despite potential positive effects in subgroups, we consider the drug dead," says Deutsche Bank. Oncothyreon collapses 61%, while Merck is -2.9% in Frankfurt. (PR) Comment! [On the Move, Healthcare]
Tuesday, October 16, 2012, 9:01 AM Threshold Pharmaceuticals (THLD) jumps 13.5% after the FDA reaches an agreement for the Phase III trial of TH-302 for the treatment of pancreatic cancer. The study will be conducted by Germany's Merck, Threshold's partner in the development of TH-302. (PR) Comment! [Healthcare, On the Move]
Friday, April 20, 2012, 6:54 AM Merck KGaA (MKGAF.PK) CEO Karl-Ludwig Kley says the German pharmaceutical company will have to slash costs and cut staffing to stay competitive. During the savings initiative, Merck plans to hold back on making any major acquisitions in the space. 1 Comment [Global & FX, Healthcare]
Wednesday, April 11, 2012, 7:48 AM Threshold Pharmaceuticals (THLD) earns a $20M milestone payment from Merck KGaA (MKGAF.PK). The payment was tied to performance of its TH-302 pancreatic cancer treatment candidate in a Phase 2 trial. Comment! [Healthcare]
Tuesday, March 6, 2012, 6:52 AM Shares of Oncothyreon (ONTY) fall 32.4% in premarket trading after Merck KgaA (MKGAF.PK) announces that studies on the experimental lung-cancer drug Stimuvax won't be completed until next year. Stimuvax is being developed by Merck KGaA under a license agreement with Oncothyreon. Comment! [Healthcare, On the Move]
Friday, February 3, 2012, 7:39 AM Shares of Threshold Pharmaceuticals (THLD) skyrocket, up 62.1%, after the biotech firm announces that it landed a deal with Merck KGaA (MKGAF.PK) to co-develop and commercialize its TH-302 cancer treatment drug. Props to M. E. Garza who nailed this call in December. Comment! [On the Move, Healthcare]
Wednesday, July 27, 2011, 3:09 AM Merck KGaA (MKGAF.PK) reports a Q2 net EPS loss of €0.40 ($0.58), vs. profit of €0.84 a year earlier. Revenue +16% to €2.56B. For 2011, Merck expects operating profit of about €1B, below guidance given in April, due to one-time adjustments. 2 Comments [Earnings, Healthcare]

MKGAF.PK Merck Kgaa Dm 5

MKGAF.PK

Merck Kgaa Dm 5